
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is focused on the innovative development of Thermo Acoustic Enhanced UltraSound (TAEUS), which aims to provide advanced tissue visualization and address the critical need for diagnostic tools in liver diseases affecting over one billion people globally. The company is anticipating FDA approval within the next year, which is expected to significantly influence the stock's valuation positively, as indicated by a net present value (NPV) analysis suggesting considerable upside potential. Furthermore, TAEUS technology promises to enhance the diagnostic accuracy and cost-effectiveness for monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), thereby positioning the company favorably in the healthcare market where effective diagnostic solutions are currently lacking.
Bears say
ENDRA Life Sciences reported a net loss of $1.2 million, translating to an earnings per share (EPS) of $(1.71), which was better than previous estimates of $(2.27). However, the company faces significant risks, including balance sheet and liquidity issues, potential failures in clinical trials, and challenges related to regulatory approvals and commercialization of its products. Additionally, external factors such as competition, macroeconomic conditions, and fluctuations in investor sentiment toward biotech and medtech stocks contribute to the negative outlook on the company's financial prospects.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares